转自：新华财经 此次贷款落地，是建行上海市分行积极响应国家"美丽中国"建设与绿色金融政策导向的具体行动，分行 通过快速学习新标准、精准对接企业需求，完成从政策解读到贷款投放的全流程服务。这笔流向食用菌 产业的资金，最终效益将体现在土壤活力的保持、农业废弃物的循环利用以及生态农业模式的推广之 中。 未来，建行上海市分行将以此为契机，深化对相关国际国内标准的研究，不断完善评估方法、产品体系 和激励机制，拓展生物多样性金融应用场景，以更加多元化的金融工具支持更多生态友好型项目，与千 企万众携手共绘"青山绿水"新图景。（邓侃） 编辑：李一帆 1月28日，建行上海市分行落地首笔专项用于支持生物多样性保护的贷款，为上海永大菌业有限公司提 供1000万元信贷支持，标志着该行在绿色金融创新领域迈出重要一步。 据了解，该笔贷款严格依照中国人民银行《生物多样性金融目录（试用稿）》相关标准发放，资金将主 要用于企业有机农产品采购，对应目录中"有机、绿色等认证农业"类别，旨在通过金融手段促进农业生 态系统的多样性维护与可持续发展。 上海永大菌业是一家专注于食用菌研发、种植、加工与销售的全产业链企业。公司长期推行绿色栽培模 式，已取得 ...

Core Viewpoint - Hualu Bio (300970.SZ) indicates that the revenue contribution from maitake mushrooms is currently low, and the company is still in the market expansion phase [1] Company Summary - The company is in the process of expanding its market presence for maitake mushrooms, which suggests potential growth opportunities in the future [1]

Core Viewpoint - The company, Hualv Biotechnology, has reported a significant increase in revenue projections for 2024, reaching 1.032 billion yuan, up from 578 million yuan in 2021, indicating strong growth in its product offerings and market expansion [1] Product Offerings - The main products of the company include enoki mushrooms, true shiitake mushrooms (which encompass varieties such as crab-flavored and white jade mushrooms), maitake mushrooms, cordyceps flowers, and deer antler mushrooms [1] - Cordyceps flowers and deer antler mushrooms are newly launched products post-IPO, showcasing the company's commitment to diversifying its product range [1] Revenue Growth - The projected revenue for 2024 is 1.032 billion yuan, which represents a notable increase compared to the 578 million yuan reported in 2021, highlighting the company's growth trajectory [1]

Core Viewpoint - The company, Hualv Biotechnology, has reported significant growth in its product offerings and revenue, projecting a revenue of 1.032 billion yuan in 2024, which represents a substantial increase from 578 million yuan in 2021, indicating a doubling of both production capacity and revenue [1]. Group 1: Product Diversification - The main products of the company include enoki mushrooms, king oyster mushrooms (including crab-flavored and white jade varieties), maitake mushrooms, cordyceps flowers, and deer antler mushrooms, with the latter two being introduced after the company's IPO [1]. - The company has achieved industrialized production of edible mushroom products under its diversified layout, with ongoing inquiries about new specialty varieties [3]. Group 2: Capacity and Revenue Growth - The company anticipates that its revenue for 2024 will reach 1.032 billion yuan, which is a notable increase from 578 million yuan in 2021, reflecting a clear growth trajectory [1]. - The company has successfully doubled its production capacity and revenue since its listing, with specific inquiries regarding the new and expanded production bases planned for 2024 and 2025 [3].

Group 1 - Jiangsu's import and export to ASEAN reached 791.73 billion yuan from January to September, a year-on-year increase of 22.8% [1] - New麦机械 (China) Co., Ltd. has seen a surge in production, with orders from Vietnam valued at 250,000 yuan, benefiting from a tariff reduction of 11,000 yuan due to the China-ASEAN Free Trade Area certificate [1] - The company applied for 190 certificates related to the China-ASEAN Free Trade Area, involving a value of nearly 71 million yuan, which is a year-on-year increase of 6.98% [1] Group 2 - Jiangsu Hualu Biotechnology Group has successfully exported 1,133.18 tons of edible mushrooms to ASEAN, marking a nearly 80% year-on-year increase [1] - The company is a key player in the local edible mushroom industry, with products like enoki mushrooms and white mushrooms entering Southeast Asia and South America [1] - A textile printing and dyeing production base was established in Vietnam, leading to over 9 million yuan in exports to ASEAN and enjoying tariff benefits exceeding 300,000 yuan [2]

Group 1 - Jiangsu's import and export to ASEAN reached 791.73 billion yuan from January to September, a year-on-year increase of 22.8% [1] - New麦机械 (China) Co., Ltd. exported baking machinery worth 250,000 yuan to Vietnam, benefiting from a tariff reduction of 11,000 yuan due to the China-ASEAN Free Trade Area origin certificate [1] - Jiangsu华绿生物科技集团 Co., Ltd. exported 1,133.18 tons of edible mushrooms to ASEAN, a nearly 80% year-on-year increase [1] Group 2 - Jiangsu红柳床单有限公司 established a textile printing and dyeing production base in Vietnam, achieving over 9 million yuan in exports to ASEAN and benefiting from over 300,000 yuan in tariff reductions [2]

Group 1 - The company, Hualv Biotechnology, announced on September 25 that it will promote its products through periodic online live broadcasts [2] - The company's mushroom products are available for sale online through platforms such as Dingdong and Meituan, as well as in major wholesale markets nationwide [2] - The company encourages consumers to purchase its products [2]

Core Viewpoint - The company is currently the only one in the industry that has industrialized production of maitake mushrooms, with no other competitors known to have similar capabilities [1] Group 1 - The company responded to investor inquiries on September 25, indicating its unique position in the market [1] - The company has not identified any other listed companies in the same industry that are engaged in industrialized production of maitake mushrooms [1]

Group 1 - The core viewpoint is that Hualu Bio has achieved a breakthrough in the industrialized cultivation technology of Grifola frondosa (Maitake mushroom), positioning itself as a leader in the industry [2] - According to Hualu Bio, it is currently the only listed company in the industry that has implemented industrialized production of Maitake products, with no other companies known to have achieved this [2]

Core Viewpoint - The company Hualu Bio (300970.SZ) has stated that its maitake mushroom products are not currently positioned in the pharmaceutical industry [1] Company Summary - Hualu Bio has clarified its current strategic focus, indicating that it has not yet ventured into the pharmaceutical sector with its maitake mushroom products [1]